APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Neonatal Genetic Disease Diagnosis

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Neonatal Genetic Disease Diagnosis Market Analysis and Forecast 2026-2032

Report ID 17419609024 June 2026184 pages

Choose your research edition.

Industry ResearchNeonatal Genetic Disease Diagnosis Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Neonatal Genetic Disease Diagnosis Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Neonatal Genetic Disease Diagnosis Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neonatal Genetic Disease Diagnosis Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Neonatal Genetic Disease Diagnosis Market Analysis and Forecast 2026-2032184 pages · $4,950 USD

Market perspective

The global Neonatal Genetic Disease Diagnosis market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Neonatal Genetic Disease Diagnosis is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Neonatal Genetic Disease Diagnosis is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Neonatal Genetic Disease Diagnosis is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Neonatal Genetic Disease Diagnosis is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Neonatal Genetic Disease Diagnosis include Abbott, PerkinElmer, Roche Diagnostics, Bio Rad, Thermo Fisher Scientific, BGI Group, Berry Genomics, Da An Gene Co., Ltd. and Illumina, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Neonatal Genetic Disease Diagnosis, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Neonatal Genetic Disease Diagnosis, also provides the revenue of main regions and countries. Of the upcoming market potential for Neonatal Genetic Disease Diagnosis, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Neonatal Genetic Disease Diagnosis revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Neonatal Genetic Disease Diagnosis market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Neonatal Genetic Disease Diagnosis revenue, projected growth trends, production technology, application and end-user industry.

Neonatal Genetic Disease Diagnosis Segment by Company

Abbott

PerkinElmer

Roche Diagnostics

Bio Rad

Thermo Fisher Scientific

BGI Group

Berry Genomics

Da An Gene Co., Ltd.

Illumina

CapitalBio Technology

Neonatal Genetic Disease Diagnosis Segment by Type

Prenatal Diagnosis

Screening for Single Gene Genetic Disease

Preimplantation Genetic Testing

Others

Neonatal Genetic Disease Diagnosis Segment by Application

Hospital

Medical Laboratory

Others

Neonatal Genetic Disease Diagnosis Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neonatal Genetic Disease Diagnosis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neonatal Genetic Disease Diagnosis and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neonatal Genetic Disease Diagnosis.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Neonatal Genetic Disease Diagnosis in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Neonatal Genetic Disease Diagnosis company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Neonatal Genetic Disease Diagnosis revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Neonatal Genetic Disease Diagnosis Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Prenatal Diagnosis Major Player Table 3. Screening for Single Gene Genetic Disease Major Player Table 4. Preimplantation Genetic Testing Major Player Table 5. Others Major Player Table 6. Global Neonatal Genetic Disease Diagnosis Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Hospital Major Player Table 8. Medical Laboratory Major Player Table 9. Others Major Player Table 10. Neonatal Genetic Disease Diagnosis Industry Trends Table 11. Neonatal Genetic Disease Diagnosis Industry Drivers Table 12. Neonatal Genetic Disease Diagnosis Industry Opportunities and Challenges Table 13. Neonatal Genetic Disease Diagnosis Industry Restraints Table 14. Global Neonatal Genetic Disease Diagnosis Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Neonatal Genetic Disease Diagnosis Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Neonatal Genetic Disease Diagnosis Market Share by Region (2021-2026) Table 17. Global Neonatal Genetic Disease Diagnosis Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Neonatal Genetic Disease Diagnosis Market Share by Region (2027-2032) Table 19. Global Neonatal Genetic Disease Diagnosis Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Neonatal Genetic Disease Diagnosis Revenue Market Share by Players (2021-2026) Table 21. Global Neonatal Genetic Disease Diagnosis Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Neonatal Genetic Disease Diagnosis Key Players Headquarters & Area Served Table 23. Global Neonatal Genetic Disease Diagnosis Players, Product Type & Application Table 24. Global Neonatal Genetic Disease Diagnosis Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Neonatal Genetic Disease Diagnosis by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Neonatal Genetic Disease Diagnosis Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Neonatal Genetic Disease Diagnosis Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Neonatal Genetic Disease Diagnosis Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Neonatal Genetic Disease Diagnosis Revenue Market Share by Type (2021-2026) Table 31. Global Neonatal Genetic Disease Diagnosis Revenue Market Share by Type (2027-2032) Table 32. Global Neonatal Genetic Disease Diagnosis Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Neonatal Genetic Disease Diagnosis Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Neonatal Genetic Disease Diagnosis Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Neonatal Genetic Disease Diagnosis Revenue Market Share by Application (2021-2026) Table 36. Global Neonatal Genetic Disease Diagnosis Revenue Market Share by Application (2027-2032) Table 37. Abbott Company Information Table 38. Abbott Business Overview Table 39. Abbott Neonatal Genetic Disease Diagnosis Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Abbott Neonatal Genetic Disease Diagnosis Product Portfolio Table 41. Abbott Recent Development Table 42. PerkinElmer Company Information Table 43. PerkinElmer Business Overview Table 44. PerkinElmer Neonatal Genetic Disease Diagnosis Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. PerkinElmer Neonatal Genetic Disease Diagnosis Product Portfolio Table 46. PerkinElmer Recent Development Table 47. Roche Diagnostics Company Information Table 48. Roche Diagnostics Business Overview Table 49. Roche Diagnostics Neonatal Genetic Disease Diagnosis Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Roche Diagnostics Neonatal Genetic Disease Diagnosis Product Portfolio Table 51. Roche Diagnostics Recent Development Table 52. Bio Rad Company Information Table 53. Bio Rad Business Overview Table 54. Bio Rad Neonatal Genetic Disease Diagnosis Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Bio Rad Neonatal Genetic Disease Diagnosis Product Portfolio Table 56. Bio Rad Recent Development Table 57. Thermo Fisher Scientific Company Information Table 58. Thermo Fisher Scientific Business Overview Table 59. Thermo Fisher Scientific Neonatal Genetic Disease Diagnosis Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Thermo Fisher Scientific Neonatal Genetic Disease Diagnosis Product Portfolio Table 61. Thermo Fisher Scientific Recent Development Table 62. BGI Group Company Information Table 63. BGI Group Business Overview Table 64. BGI Group Neonatal Genetic Disease Diagnosis Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. BGI Group Neonatal Genetic Disease Diagnosis Product Portfolio Table 66. BGI Group Recent Development Table 67. Berry Genomics Company Information Table 68. Berry Genomics Business Overview Table 69. Berry Genomics Neonatal Genetic Disease Diagnosis Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Berry Genomics Neonatal Genetic Disease Diagnosis Product Portfolio Table 71. Berry Genomics Recent Development Table 72. Da An Gene Co., Ltd. Company Information Table 73. Da An Gene Co., Ltd. Business Overview Table 74. Da An Gene Co., Ltd. Neonatal Genetic Disease Diagnosis Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Da An Gene Co., Ltd. Neonatal Genetic Disease Diagnosis Product Portfolio Table 76. Da An Gene Co., Ltd. Recent Development Table 77. Illumina Company Information Table 78. Illumina Business Overview Table 79. Illumina Neonatal Genetic Disease Diagnosis Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. Illumina Neonatal Genetic Disease Diagnosis Product Portfolio Table 81. Illumina Recent Development Table 82. CapitalBio Technology Company Information Table 83. CapitalBio Technology Business Overview Table 84. CapitalBio Technology Neonatal Genetic Disease Diagnosis Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. CapitalBio Technology Neonatal Genetic Disease Diagnosis Product Portfolio Table 86. CapitalBio Technology Recent Development Table 87. North America Neonatal Genetic Disease Diagnosis Revenue by Type (2021-2026) & (US$ Million) Table 88. North America Neonatal Genetic Disease Diagnosis Revenue by Type (2027-2032) & (US$ Million) Table 89. North America Neonatal Genetic Disease Diagnosis Revenue by Application (2021-2026) & (US$ Million) Table 90. North America Neonatal Genetic Disease Diagnosis Revenue by Application (2027-2032) & (US$ Million) Table 91. North America Neonatal Genetic Disease Diagnosis Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 92. North America Neonatal Genetic Disease Diagnosis Revenue by Country (2021-2026) & (US$ Million) Table 93. North America Neonatal Genetic Disease Diagnosis Revenue by Country (US$ Million) & (2027-2032) Table 94. Europe Neonatal Genetic Disease Diagnosis Revenue by Type (2021-2026) & (US$ Million) Table 95. Europe Neonatal Genetic Disease Diagnosis Revenue by Type (2027-2032) & (US$ Million) Table 96. Europe Neonatal Genetic Disease Diagnosis Revenue by Application (2021-2026) & (US$ Million) Table 97. Europe Neonatal Genetic Disease Diagnosis Revenue by Application (2027-2032) & (US$ Million) Table 98. Europe Neonatal Genetic Disease Diagnosis Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 99. Europe Neonatal Genetic Disease Diagnosis Revenue by Country (2021-2026) & (US$ Million) Table 100. Europe Neonatal Genetic Disease Diagnosis Revenue by Country (US$ Million) & (2027-2032) Table 101. China Neonatal Genetic Disease Diagnosis Revenue by Type (2021-2026) & (US$ Million) Table 102. China Neonatal Genetic Disease Diagnosis Revenue by Type (2027-2032) & (US$ Million) Table 103. China Neonatal Genetic Disease Diagnosis Revenue by Application (2021-2026) & (US$ Million) Table 104. China Neonatal Genetic Disease Diagnosis Revenue by Application (2027-2032) & (US$ Million) Table 105. Asia Neonatal Genetic Disease Diagnosis Revenue by Type (2021-2026) & (US$ Million) Table 106. Asia Neonatal Genetic Disease Diagnosis Revenue by Type (2027-2032) & (US$ Million) Table 107. Asia Neonatal Genetic Disease Diagnosis Revenue by Application (2021-2026) & (US$ Million) Table 108. Asia Neonatal Genetic Disease Diagnosis Revenue by Application (2027-2032) & (US$ Million) Table 109. Asia Neonatal Genetic Disease Diagnosis Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 110. Asia Neonatal Genetic Disease Diagnosis Revenue by Region (US$ Million) & (2021-2026) Table 111. Asia Neonatal Genetic Disease Diagnosis Revenue by Region (US$ Million) & (2027-2032) Table 112. SAMEA Neonatal Genetic Disease Diagnosis Revenue by Type (2021-2026) & (US$ Million) Table 113. SAMEA Neonatal Genetic Disease Diagnosis Revenue by Type (2027-2032) & (US$ Million) Table 114. SAMEA Neonatal Genetic Disease Diagnosis Revenue by Application (2021-2026) & (US$ Million) Table 115. SAMEA Neonatal Genetic Disease Diagnosis Revenue by Application (2027-2032) & (US$ Million) Table 116. SAMEA Neonatal Genetic Disease Diagnosis Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 117. SAMEA Neonatal Genetic Disease Diagnosis Revenue by Country (2021-2026) & (US$ Million) Table 118. SAMEA Neonatal Genetic Disease Diagnosis Revenue by Country (US$ Million) & (2027-2032) Table 119. Research Programs/Design for This Report Table 120. Authors List of This Report Table 121. Secondary Sources Table 122. Primary Sources List of Figures Figure 1. Neonatal Genetic Disease Diagnosis Image Figure 2. Global Neonatal Genetic Disease Diagnosis Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neonatal Genetic Disease Diagnosis Market Size Share 2021 VS 2025 VS 2032 Figure 4. Prenatal Diagnosis Image Figure 5. Screening for Single Gene Genetic Disease Image Figure 6. Preimplantation Genetic Testing Image Figure 7. Others Image Figure 8. Global Neonatal Genetic Disease Diagnosis Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Neonatal Genetic Disease Diagnosis Market Size Share 2021 VS 2025 VS 2032 Figure 10. Hospital Image Figure 11. Medical Laboratory Image Figure 12. Others Image Figure 13. Global Neonatal Genetic Disease Diagnosis Market Size (US$ Million) & (2021-2032) Figure 14. Global Neonatal Genetic Disease Diagnosis Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Neonatal Genetic Disease Diagnosis Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Neonatal Genetic Disease Diagnosis Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Neonatal Genetic Disease Diagnosis Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Neonatal Genetic Disease Diagnosis Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Neonatal Genetic Disease Diagnosis Revenue Market Share by Type (2021-2032) Figure 21. Global Neonatal Genetic Disease Diagnosis Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Neonatal Genetic Disease Diagnosis Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Neonatal Genetic Disease Diagnosis Revenue Market Share by Application (2021-2032) Figure 24. North America Neonatal Genetic Disease Diagnosis Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Neonatal Genetic Disease Diagnosis Revenue Share by Type (2021-2032) Figure 26. North America Neonatal Genetic Disease Diagnosis Revenue Share by Application (2021-2032) Figure 27. North America Neonatal Genetic Disease Diagnosis Revenue Share by Country (2021-2032) Figure 28. United States Neonatal Genetic Disease Diagnosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Neonatal Genetic Disease Diagnosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Neonatal Genetic Disease Diagnosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Neonatal Genetic Disease Diagnosis Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Neonatal Genetic Disease Diagnosis Revenue Share by Type (2021-2032) Figure 33. Europe Neonatal Genetic Disease Diagnosis Revenue Share by Application (2021-2032) Figure 34. Europe Neonatal Genetic Disease Diagnosis Revenue Share by Country (2021-2032) Figure 35. Germany Neonatal Genetic Disease Diagnosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Neonatal Genetic Disease Diagnosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Neonatal Genetic Disease Diagnosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Neonatal Genetic Disease Diagnosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Neonatal Genetic Disease Diagnosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Neonatal Genetic Disease Diagnosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Neonatal Genetic Disease Diagnosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Neonatal Genetic Disease Diagnosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Neonatal Genetic Disease Diagnosis Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Neonatal Genetic Disease Diagnosis Revenue Share by Type (2021-2032) Figure 45. China Neonatal Genetic Disease Diagnosis Revenue Share by Application (2021-2032) Figure 46. Asia Neonatal Genetic Disease Diagnosis Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Neonatal Genetic Disease Diagnosis Revenue Share by Type (2021-2032) Figure 48. Asia Neonatal Genetic Disease Diagnosis Revenue Share by Application (2021-2032) Figure 49. Asia Neonatal Genetic Disease Diagnosis Revenue Share by Region (2021-2032) Figure 50. Japan Neonatal Genetic Disease Diagnosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Neonatal Genetic Disease Diagnosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Neonatal Genetic Disease Diagnosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Neonatal Genetic Disease Diagnosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Neonatal Genetic Disease Diagnosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Neonatal Genetic Disease Diagnosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Neonatal Genetic Disease Diagnosis Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Neonatal Genetic Disease Diagnosis Revenue Share by Type (2021-2032) Figure 58. SAMEA Neonatal Genetic Disease Diagnosis Revenue Share by Application (2021-2032) Figure 59. SAMEA Neonatal Genetic Disease Diagnosis Revenue Share by Country (2021-2032) Figure 60. Brazil Neonatal Genetic Disease Diagnosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Neonatal Genetic Disease Diagnosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Neonatal Genetic Disease Diagnosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Neonatal Genetic Disease Diagnosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Neonatal Genetic Disease Diagnosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Neonatal Genetic Disease Diagnosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Neonatal Genetic Disease Diagnosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Neonatal Genetic Disease Diagnosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Neonatal Genetic Disease Diagnosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Neonatal Genetic Disease Diagnosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Neonatal Genetic Disease Diagnosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Prenatal Diagnosis
  • Screening for Single Gene Genetic Disease
  • Preimplantation Genetic Testing
  • Others
Applications
  • Hospital
  • Medical Laboratory
  • Others
Companies covered
  • Abbott
  • PerkinElmer
  • Roche Diagnostics
  • Bio Rad
  • Thermo Fisher Scientific
  • BGI Group
  • Berry Genomics
  • Da An Gene Co., Ltd.
  • Illumina
  • CapitalBio Technology

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Neonatal Genetic Disease Diagnosis Market by Type
  3. 1.2.1 Global Neonatal Genetic Disease Diagnosis Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Prenatal Diagnosis
  5. 1.2.3 Screening for Single Gene Genetic Disease
  6. 1.2.4 Preimplantation Genetic Testing
  7. 1.2.5 Others
  8. 1.3 Neonatal Genetic Disease Diagnosis Market by Application
  9. 1.3.1 Global Neonatal Genetic Disease Diagnosis Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Hospital
  11. 1.3.3 Medical Laboratory
  12. 1.3.4 Others
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Neonatal Genetic Disease Diagnosis Market Dynamics
  1. 2.1 Neonatal Genetic Disease Diagnosis Industry Trends
  2. 2.2 Neonatal Genetic Disease Diagnosis Industry Drivers
  3. 2.3 Neonatal Genetic Disease Diagnosis Industry Opportunities and Challenges
  4. 2.4 Neonatal Genetic Disease Diagnosis Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Neonatal Genetic Disease Diagnosis Market Perspective (2021-2032)
  2. 3.2 Global Neonatal Genetic Disease Diagnosis Growth Trends by Region
  3. 3.2.1 Global Neonatal Genetic Disease Diagnosis Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Neonatal Genetic Disease Diagnosis Market Size by Region (2021-2026)
  5. 3.2.3 Global Neonatal Genetic Disease Diagnosis Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Neonatal Genetic Disease Diagnosis Revenue by Players
  2. 4.1.1 Global Neonatal Genetic Disease Diagnosis Revenue by Players (2021-2026)
  3. 4.1.2 Global Neonatal Genetic Disease Diagnosis Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Neonatal Genetic Disease Diagnosis Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Neonatal Genetic Disease Diagnosis Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Neonatal Genetic Disease Diagnosis Key Players Headquarters & Area Served
  7. 4.4 Global Neonatal Genetic Disease Diagnosis Players, Product Type & Application
  8. 4.5 Global Neonatal Genetic Disease Diagnosis Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Neonatal Genetic Disease Diagnosis Market CR5 and HHI
  11. 4.6.3 2025 Neonatal Genetic Disease Diagnosis Tier 1, Tier 2, and Tier 3
5 Neonatal Genetic Disease Diagnosis Market Size by Type
  1. 5.1 Global Neonatal Genetic Disease Diagnosis Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Neonatal Genetic Disease Diagnosis Revenue by Type (2021-2032)
  3. 5.3 Global Neonatal Genetic Disease Diagnosis Revenue Market Share by Type (2021-2032)
6 Neonatal Genetic Disease Diagnosis Market Size by Application
  1. 6.1 Global Neonatal Genetic Disease Diagnosis Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Neonatal Genetic Disease Diagnosis Revenue by Application (2021-2032)
  3. 6.3 Global Neonatal Genetic Disease Diagnosis Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Abbott
  2. 7.1.1 Abbott Company Information
  3. 7.1.2 Abbott Business Overview
  4. 7.1.3 Abbott Neonatal Genetic Disease Diagnosis Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Abbott Neonatal Genetic Disease Diagnosis Product Portfolio
  6. 7.1.5 Abbott Recent Developments
  7. 7.2 PerkinElmer
  8. 7.2.1 PerkinElmer Company Information
  9. 7.2.2 PerkinElmer Business Overview
  10. 7.2.3 PerkinElmer Neonatal Genetic Disease Diagnosis Revenue and Gross Margin (2021-2026)
  11. 7.2.4 PerkinElmer Neonatal Genetic Disease Diagnosis Product Portfolio
  12. 7.2.5 PerkinElmer Recent Developments
  13. 7.3 Roche Diagnostics
  14. 7.3.1 Roche Diagnostics Company Information
  15. 7.3.2 Roche Diagnostics Business Overview
  16. 7.3.3 Roche Diagnostics Neonatal Genetic Disease Diagnosis Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Roche Diagnostics Neonatal Genetic Disease Diagnosis Product Portfolio
  18. 7.3.5 Roche Diagnostics Recent Developments
  19. 7.4 Bio Rad
  20. 7.4.1 Bio Rad Company Information
  21. 7.4.2 Bio Rad Business Overview
  22. 7.4.3 Bio Rad Neonatal Genetic Disease Diagnosis Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Bio Rad Neonatal Genetic Disease Diagnosis Product Portfolio
  24. 7.4.5 Bio Rad Recent Developments
  25. 7.5 Thermo Fisher Scientific
  26. 7.5.1 Thermo Fisher Scientific Company Information
  27. 7.5.2 Thermo Fisher Scientific Business Overview
  28. 7.5.3 Thermo Fisher Scientific Neonatal Genetic Disease Diagnosis Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Thermo Fisher Scientific Neonatal Genetic Disease Diagnosis Product Portfolio
  30. 7.5.5 Thermo Fisher Scientific Recent Developments
  31. 7.6 BGI Group
  32. 7.6.1 BGI Group Company Information
  33. 7.6.2 BGI Group Business Overview
  34. 7.6.3 BGI Group Neonatal Genetic Disease Diagnosis Revenue and Gross Margin (2021-2026)
  35. 7.6.4 BGI Group Neonatal Genetic Disease Diagnosis Product Portfolio
  36. 7.6.5 BGI Group Recent Developments
  37. 7.7 Berry Genomics
  38. 7.7.1 Berry Genomics Company Information
  39. 7.7.2 Berry Genomics Business Overview
  40. 7.7.3 Berry Genomics Neonatal Genetic Disease Diagnosis Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Berry Genomics Neonatal Genetic Disease Diagnosis Product Portfolio
  42. 7.7.5 Berry Genomics Recent Developments
  43. 7.8 Da An Gene Co., Ltd.
  44. 7.8.1 Da An Gene Co., Ltd. Company Information
  45. 7.8.2 Da An Gene Co., Ltd. Business Overview
  46. 7.8.3 Da An Gene Co., Ltd. Neonatal Genetic Disease Diagnosis Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Da An Gene Co., Ltd. Neonatal Genetic Disease Diagnosis Product Portfolio
  48. 7.8.5 Da An Gene Co., Ltd. Recent Developments
  49. 7.9 Illumina
  50. 7.9.1 Illumina Company Information
  51. 7.9.2 Illumina Business Overview
  52. 7.9.3 Illumina Neonatal Genetic Disease Diagnosis Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Illumina Neonatal Genetic Disease Diagnosis Product Portfolio
  54. 7.9.5 Illumina Recent Developments
  55. 7.10 CapitalBio Technology
  56. 7.10.1 CapitalBio Technology Company Information
  57. 7.10.2 CapitalBio Technology Business Overview
  58. 7.10.3 CapitalBio Technology Neonatal Genetic Disease Diagnosis Revenue and Gross Margin (2021-2026)
  59. 7.10.4 CapitalBio Technology Neonatal Genetic Disease Diagnosis Product Portfolio
  60. 7.10.5 CapitalBio Technology Recent Developments
8 North America
  1. 8.1 North America Neonatal Genetic Disease Diagnosis Revenue (2021-2032)
  2. 8.2 North America Neonatal Genetic Disease Diagnosis Revenue by Type (2021-2032)
  3. 8.2.1 North America Neonatal Genetic Disease Diagnosis Revenue by Type (2021-2026)
  4. 8.2.2 North America Neonatal Genetic Disease Diagnosis Revenue by Type (2027-2032)
  5. 8.3 North America Neonatal Genetic Disease Diagnosis Revenue Share by Type (2021-2032)
  6. 8.4 North America Neonatal Genetic Disease Diagnosis Revenue by Application (2021-2032)
  7. 8.4.1 North America Neonatal Genetic Disease Diagnosis Revenue by Application (2021-2026)
  8. 8.4.2 North America Neonatal Genetic Disease Diagnosis Revenue by Application (2027-2032)
  9. 8.5 North America Neonatal Genetic Disease Diagnosis Revenue Share by Application (2021-2032)
  10. 8.6 North America Neonatal Genetic Disease Diagnosis Revenue by Country
  11. 8.6.1 North America Neonatal Genetic Disease Diagnosis Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Neonatal Genetic Disease Diagnosis Revenue by Country (2021-2026)
  13. 8.6.3 North America Neonatal Genetic Disease Diagnosis Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Neonatal Genetic Disease Diagnosis Revenue (2021-2032)
  2. 9.2 Europe Neonatal Genetic Disease Diagnosis Revenue by Type (2021-2032)
  3. 9.2.1 Europe Neonatal Genetic Disease Diagnosis Revenue by Type (2021-2026)
  4. 9.2.2 Europe Neonatal Genetic Disease Diagnosis Revenue by Type (2027-2032)
  5. 9.3 Europe Neonatal Genetic Disease Diagnosis Revenue Share by Type (2021-2032)
  6. 9.4 Europe Neonatal Genetic Disease Diagnosis Revenue by Application (2021-2032)
  7. 9.4.1 Europe Neonatal Genetic Disease Diagnosis Revenue by Application (2021-2026)
  8. 9.4.2 Europe Neonatal Genetic Disease Diagnosis Revenue by Application (2027-2032)
  9. 9.5 Europe Neonatal Genetic Disease Diagnosis Revenue Share by Application (2021-2032)
  10. 9.6 Europe Neonatal Genetic Disease Diagnosis Revenue by Country
  11. 9.6.1 Europe Neonatal Genetic Disease Diagnosis Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Neonatal Genetic Disease Diagnosis Revenue by Country (2021-2026)
  13. 9.6.3 Europe Neonatal Genetic Disease Diagnosis Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Neonatal Genetic Disease Diagnosis Revenue (2021-2032)
  2. 10.2 China Neonatal Genetic Disease Diagnosis Revenue by Type (2021-2032)
  3. 10.2.1 China Neonatal Genetic Disease Diagnosis Revenue by Type (2021-2026)
  4. 10.2.2 China Neonatal Genetic Disease Diagnosis Revenue by Type (2027-2032)
  5. 10.3 China Neonatal Genetic Disease Diagnosis Revenue Share by Type (2021-2032)
  6. 10.4 China Neonatal Genetic Disease Diagnosis Revenue by Application (2021-2032)
  7. 10.4.1 China Neonatal Genetic Disease Diagnosis Revenue by Application (2021-2026)
  8. 10.4.2 China Neonatal Genetic Disease Diagnosis Revenue by Application (2027-2032)
  9. 10.5 China Neonatal Genetic Disease Diagnosis Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Neonatal Genetic Disease Diagnosis Revenue (2021-2032)
  2. 11.2 Asia Neonatal Genetic Disease Diagnosis Revenue by Type (2021-2032)
  3. 11.2.1 Asia Neonatal Genetic Disease Diagnosis Revenue by Type (2021-2026)
  4. 11.2.2 Asia Neonatal Genetic Disease Diagnosis Revenue by Type (2027-2032)
  5. 11.3 Asia Neonatal Genetic Disease Diagnosis Revenue Share by Type (2021-2032)
  6. 11.4 Asia Neonatal Genetic Disease Diagnosis Revenue by Application (2021-2032)
  7. 11.4.1 Asia Neonatal Genetic Disease Diagnosis Revenue by Application (2021-2026)
  8. 11.4.2 Asia Neonatal Genetic Disease Diagnosis Revenue by Application (2027-2032)
  9. 11.5 Asia Neonatal Genetic Disease Diagnosis Revenue Share by Application (2021-2032)
  10. 11.6 Asia Neonatal Genetic Disease Diagnosis Revenue by Country
  11. 11.6.1 Asia Neonatal Genetic Disease Diagnosis Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Neonatal Genetic Disease Diagnosis Revenue by Country (2021-2026)
  13. 11.6.3 Asia Neonatal Genetic Disease Diagnosis Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Neonatal Genetic Disease Diagnosis Revenue (2021-2032)
  2. 12.2 SAMEA Neonatal Genetic Disease Diagnosis Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Neonatal Genetic Disease Diagnosis Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Neonatal Genetic Disease Diagnosis Revenue by Type (2027-2032)
  5. 12.3 SAMEA Neonatal Genetic Disease Diagnosis Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Neonatal Genetic Disease Diagnosis Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Neonatal Genetic Disease Diagnosis Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Neonatal Genetic Disease Diagnosis Revenue by Application (2027-2032)
  9. 12.5 SAMEA Neonatal Genetic Disease Diagnosis Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Neonatal Genetic Disease Diagnosis Revenue by Country
  11. 12.6.1 SAMEA Neonatal Genetic Disease Diagnosis Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Neonatal Genetic Disease Diagnosis Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Neonatal Genetic Disease Diagnosis Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst